Zolpidem 5 mg generic tabletst
Zolpidem 5 mg generic tablets is an inexpensive drug used to treat insomnia. It is more popular than comparable drugs. It is available in generic and brand versions.
DOSAGE AND ADMINISTRATION
• Use the lowest dose effective for the patient and must not exceed a total of 12.5 mg daily
• Recommended initial dose is a single dose of 6.25 mg for women, and a single dose of 6.25 or 12.5 mg for men, immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening.
• Geriatric patients and patients with mild to moderate hepatic impairment: Recommended dose is 6.25 mg for men and women;
• Lower doses of CNS depressants may be necessary when taken concomitantly with AMBIEN CR;
• Tablets to be swallowed whole, not to be crushed, divided or chewed;
• The effect of AMBIEN CR may be slowed if taken with or immediately after a meal;
DOSAGE FORMS AND STRENGTHS
Tablets Zolpidem ,Ambien, Intermezzo, Zolpimist : 6.25 mg and 12.5 mg extended-release tablets. Tablets not scored.
WARNINGS AND PRECAUTION
• CNS depressant effects: Impaired alertness and motor coordination, including risk of morning impairment. Caution patients against driving and other activities requiring complete mental alertness the morning after use.
Most commonly observed adverse reactions (> 10% in either elderly or adult patients) are: headache, next-day somnolence and dizziness.
• CNS depressants, including alcohol: Possible adverse additive CNSdepressant effects.
• Imipramine: Decreased alertness observed.
• Chlorpromazine: Impaired alertness and psychomotor performance observed;
• CYP3A4 inducers (e.g. rifampin): Combination use may decrease effect;
• CYP3A4 inhibitors (e.g. ketoconazole): Combination use may increase effect;
USE IN SPECIFIC POPULATION
• Pregnancy: Based on animal data may cause fetal harm (8.1)
• Pediatric use: Safety and effectiveness not established. Hallucinations (incidence rate 7%) and other psychiatric and/or nervous system adverse reactions were observed frequently in a study of pediatric patients with Attention-Deficit/Hyperactivity Disorder.